Retrophin, Inc. (RTRX) Downgraded to “Strong Sell” at Zacks Investment Research
Zacks Investment Research lowered shares of Retrophin, Inc. (NASDAQ:RTRX) from a hold rating to a strong sell rating in a research report report published on Tuesday morning.
According to Zacks, “Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company’s approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. “
Several other research analysts also recently commented on the company. BMO Capital Markets reaffirmed a buy rating and issued a $44.00 price target on shares of Retrophin in a research report on Friday, October 6th. BidaskClub raised Retrophin from a buy rating to a strong-buy rating in a research report on Thursday, August 24th. Finally, ValuEngine raised Retrophin from a sell rating to a hold rating in a research report on Friday, August 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Retrophin presently has an average rating of Buy and an average price target of $36.00.
Retrophin (NASDAQ:RTRX) traded down $0.01 on Tuesday, reaching $21.34. The company had a trading volume of 226,800 shares, compared to its average volume of 335,120. Retrophin has a 12-month low of $15.55 and a 12-month high of $26.44. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.88 and a quick ratio of 3.83.
Retrophin (NASDAQ:RTRX) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.21). Retrophin had a negative return on equity of 10.13% and a negative net margin of 33.79%. The company had revenue of $40.34 million during the quarter, compared to analyst estimates of $40.51 million. During the same quarter last year, the firm posted ($0.09) earnings per share. The firm’s revenue for the quarter was up 18.8% compared to the same quarter last year. equities analysts expect that Retrophin will post -1.25 earnings per share for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Trexquant Investment LP bought a new position in Retrophin in the 3rd quarter worth approximately $203,000. SG Americas Securities LLC increased its position in Retrophin by 1.8% in the 2nd quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock worth $158,000 after buying an additional 146 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in Retrophin in the 3rd quarter worth approximately $212,000. Legal & General Group Plc increased its position in shares of Retrophin by 4.3% during the second quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after purchasing an additional 355 shares during the period. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Retrophin during the third quarter valued at approximately $249,000.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.